Answers are grounded in this paper and cite their sources.
Meta-analysis reveals the impact of methotrexate dosage on toxicity types in pediatric malignancy patients, suggesting treatment adjustments may improve outcomes.
Objective: An anticancer and anti-inflammatory drug broadly applied to treat various diseases is Methotrexate (MTX). A variety of patients are more prone to toxicity, and a variety of them resist chemotherapy. The relationship between MTX-related toxicities and pharmacogenetics has been investigated by most studies, and there is not much data on the relationship between the type of toxicity and MTX dosage.Material and Methods: In this meta-analysis, 63 studies focusing on the association between MTX dosage and MTX-related toxicities were evaluated.Results: As shown in our pooled analysis, mucositis has a higher prevalence (P= 0.3, 95%CI (0.21, 0.4)) versus other toxicities, followed by hepatic toxicity (P= 0.25, 95%CI (0 0.18, 0.32)), and hematologic toxicity (P= 0.42, 95%CI (0.25, 0.6)); however, the lowest prevalence was in dermal toxicity (P= 0.17 [95%CI (0.07, 0.28)). According to the result, a significant prevalence was seen in different dosages in all toxicity (except the hematologic toxicity). Also, the 12 mg dose exhibited higher toxicity than other doses.Conclusions: One of the major leading treatment restrictions is MTX-related toxicities. Lower response to treatment, especially in pediatrics, accompanies this therapy interference. Treatment efficacy can be improved by understanding susceptible factors for developing adverse events and replacing MTX.
No takes yet. Share an insight, caveat, or question.
Malehi et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: